Innovator’s Pitch Challenge

Vote for Us

Interested in Connecting? Please contact:
Yong Zhao, MD, PhD
President
yong.zhao@thronebio.com

Message the company or request a 1:1 meeting here

Throne is an American therapeutics company aimed at commercializing a novel stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. The patented technology is recognized as the leading “practical cure project” for type 1 diabetes among 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like treatment that fundamentally “resets” a patient’s immune system and corrects the underlying autoimmunity. 200+ patients between the ages of 3 and 70 have been treated in 10 years of clinical research in Spain, China, and US. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy. Many patients reduced insulin dosing and some have become insulin independent. This technology has been successfully tried in more than 10 autoimmune diseases including alopecia, lupus, fibrosis, and scleroderma. This therapy is ready to use and is approved to begin three FDA phase 2 clinical trials (type 1 diabetes, alopecia areata, COVID-19). Throne is looking to raise $5M to complete US FDA phase 2 through to commercialization. Throne is open to parternships, joint ventures, investments, and license arrangements.